Vitrakvi (larotrectinib) / Bayer, Pfizer - LARVOL DELTA

Distinct adverse event profiles of larotrectinib, entrectinib, and repotrectinib: a FAERS disproportionality analysis (ESMO 2026) - No abstract available

Adverse events • Oncology

Long-term efficacy and safety of larotrectinib in patients with TRK fusion thyroid cancer: An updated analysis (ESMO 2026) - No abstract available

Clinical • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Long-term efficacy and safety of larotrectinib in patients with TRK fusion solid tumours: NAVIGATE final analysis (ESMO 2026) - No abstract available

Clinical • Oncology • Solid Tumor

Real-world outcomes of Larotrectinib in Solid Tumors with Tropomyosin Receptor Kinase Fusion (GETNE S2411 / SPAINTRK) (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Oncology • Solid Tumor

Real-world study of larotrectinib in patients with TRK fusion solid tumours: ON-TRK updated analysis (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Oncology • Solid Tumor

Impact of Neoadjuvant TKI Therapy on Tumor Reduction and Resectability in Locally Advanced Thyroid Carcinoma (ETA 2026) - "Therapies included selective (dabrafenib/trametinib, entrectinib, larotrectinib, selpercatinib) and multikinase inhibitors (lenvatinib, cabozantinib, vandetanib)... Neoadjuvant TKI therapy demonstrated promising results in locally advanced thyroid carcinoma, achieving high disease control rates and enabling surgical resection in over one-third of cases. Outcomes were comparable between selective and multikinase TKIs, and meaningful responses were observed across histological subtypes, although survival remained significantly longer in differentiated tumors. These findings, representing one of the largest single-center cohorts, reinforce the growing role of neoadjuvant therapy in multidisciplinary management of advanced thyroid cancer."

Clinical • Metastases • Oncology • Solid Tumor • Thyroid Gland Carcinoma

How to manage radioiodine-refractory thyroid cancer in the era of precision medicine. (PubMed, Drugs Context) - "Three multi-kinase inhibitors have been approved for this indication: lenvatinib and sorafenib as a first-line option and cabozantinib as a second-line option...Thus, additional selective inhibitors have been approved: larotrectinib and entrectinib for NTRK + tumours, selpercatinib and pralsetinib for RET + tumours, and crizotinib, alectinib and lorlatinib for ALK + tumours. Such a personalized approach increases clinical benefit whilst minimizing adverse events. Future studies should focus on the combination of tyrosine kinase inhibitors and immune-checkpoint inhibitors; currently, there is no strong evidence that redifferentiation strategies add clinical benefit in terms of overall survival or progression-free survival."

Journal • Review • Oncology • Solid Tumor • Thyroid Gland Carcinoma • ALK • NTRK

Genetic landscape of a series of sporadic Differentiated Thyroid Carcinoma (spDTC) patients: clinical utility of Next Generation Sequencing (NGS) in therapeutic strategy (ETA 2026) - "In 3/7 BRAF V600E patients Dabrafenib in combination with Trametinib was initiated ( n 2 patients with partial response, n 1 patient with initially mixed response, finally succumbed to the disease). In the PTEN patient, Lenvatinib plus Pembrolizumab was initiated with mixed response for a period of 18 months before disease progression was documented. Clinical utility of NGS in aggressive DTC provides information regarding prognosis while in locally advanced and/or metastatic disease is the sine qua non of precision medicine implementation as, apart from targetable mutations, it unravels targetable rearrangements, as well."

Biomarker • Clinical • Next-generation sequencing • CNS Disorders • Oncology • Solid Tumor • Thyroid Gland Carcinoma • BRAF • ETV6 • mTOR • NCOA4 • NRAS • NTRK3 • PIK3CA • PTEN

Neurotrophin signaling in synovial fibroblasts sustains pathological vascular maturation in rheumatoid arthritis (ACR Convergence 2026) - "Fibroblast-derived neurotrophin signaling is a critical driver of pathologic vascular maturation in RA and represents a previously unrecognized mechanism contributing to persistent synovial remodeling. Our findings suggest that fibroblast-derived neurotrophin signaling is a critical pathway in sustaining mature blood vessels in RA synovia, and that neurotrophin inhibitors reverse abnormal vascular maturation in RA."

Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • ACTA2 • CD31 • NGF • NGFR • NOTCH3 • NTF3 • NTRK2 • PECAM1 • RGS5

NTRK-fused gliomas inadults:clinical, radiological andhistomolecularfeatures (EANO 2026) - "Adult NTRK-fused glial and glioneuronal tumors represent a rare and heterogeneous subgroup of tumors with responses to TRK inhibitors observed in nearly 50% of cases. Therefore, testing for NTRK fusion may provide additional therapeutic options for patients with glial and glioneuronal tumors and should be considered in younger patients and in tumors with unusual histology and/or unexpectedly aggressive behavior."

Clinical • Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Glioneuronal Tumor • High Grade Glioma • Low Grade Glioma • Oncology • Pleomorphic Xanthoastrocytoma • Solid Tumor • CDKN2A • CDKN2B • IDH1 • NTRK • NTRK1 • NTRK2 • NTRK3 • PTEN • TERT • TFG • TP53

Enhancing pathological diagnosis and guiding personalised therapy in salivary gland tumors with a clinically validated 107-gene molecular panel (ECP 2026) - "This included the successful use of the TRK inhibitor Larotrectinib in one patient with a rapidly progressive, refractory tumor reclassified from a myoepithelial carcinoma to an NTRK-rearranged neoplasm, and in another patient with an recurrent and metastatic secretory carcinoma—originally misdiagnosed in both primary and recurrent settings—whose diagnosis was corrected by the panel, leading to targeted therapy and resulting in near-complete resolution of thoracic metastases. This study demonstrates the powerful diagnostic utility of the 107-gene panel, which resolves ambiguous SGT cases and uncovers novel molecular events. By expanding the molecular landscape with previously unreported driver alterations and refining diagnostic boundaries, this work lays the critical groundwork for precise patient stratification, thereby bridging the gap between complex diagnosis and emerging targeted therapies."

Clinical • Clear Cell Carcinoma • Oncology • Rhabdoid Tumor • Salivary Gland Cancer • Squamous Cell Carcinoma • AFF2 • ATF1 • CDH1 • EWSR1 • NTRK • SS18 • ZBTB7A

Infant-Type Hemispheric Glioma With NTRK Fusion Responds to Larotrectinib. (PubMed, Cureus) - "Following surgical resection, targeted therapy with an NTRK inhibitor was initiated, resulting in a sustained clinical and radiologic response. This case underscores the importance of integrated histologic and molecular evaluation in establishing the diagnosis and guiding management of these tumors, as well as the clinical relevance of identifying targetable alterations."

Journal • Brain Cancer • Fibrosis • Glioma • High Grade Glioma • Oncology • Pediatrics • Solid Tumor • ALK • NTRK • NTRK1 • ROS1 • TPM3

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. (PubMed, Eur J Cancer) - P2 | "Larotrectinib demonstrated long durability, extended survival and manageable safety in patients with TRK fusion GI cancer, including those with MSI-H CRC. This supports the wider adoption of next-generation sequencing testing for NTRK gene fusions in patients with GI cancer."

Journal • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatocellular Cancer • Hepatology • Liver Cancer • Microsatellite Instability • Oncology • Pancreatic Cancer • Solid Tumor • MSI • NTRK

Long-Term Efficacy and Safety of Larotrectinib in Patients with TRK Fusion Differentiated Thyroid Carcinoma: An Updated Analysis (ATA 2026) - No abstract available

Clinical • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Updated Efficacy, Safety, and Genomic Data in Patients With Trk Fusion Lung Cancer Treated With Larotrectinib (IASLC-WCLC 2025) - P1, P2 | "Conclusions : Larotrectinib continues to demonstrate rapid and durable responses, extended survival benefit, and a favorable safety profile in patients with advanced TRK fusion lung cancer. These results support the wider adoption of NGS panels that incorporate NTRK gene fusion detection."

Clinical • Genomic data • Lung Cancer • Oncology • Solid Tumor • KRAS • NTRK • NTRK1 • TP53

ABDOMINAL RADICAL TRACHELECTOMY IN NTRK FUSION POSITIVE SARCOMA OF THE CERVIX (IGCS 2026) - "Tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusions leading to constitutive activation of TRK signaling pathways, demonstrate high response rates to targeted TRK inhibitors such as Larotrectinib...Conclusion/Implications: Final pathology confirmed a pathological complete response, and the patient remains disease-free on follow-up. This case highlights the relevance of molecular diagnostics and the potential of neoadjuvant TRK inhibition in downstaging NTRK fusion-positive cervical sarcomas, enabling fertility-preserving approaches in highly selected patients, after thorough (multidisc iplinary) counseling and with close surveillance."

Oncology • Sarcoma • Solid Tumor • Uterine Cancer • NTRK

Tissue-Agnostic Cancer Therapy Approvals. (PubMed, Hematol Oncol Clin North Am) - "In stark contrast to conventional cancer treatments that categorize malignancies based on their tissue of origin (eg, breast, lung, renal cell, etc), tumor-agnostic therapies transcend histologic boundaries, honing in on the genetic and molecular attributes of tumors, regardless of their location. This article offers a comprehensive review of the current landscape of tissue-agnostic cancer therapies and provides clinical insights to empower surgical oncologists with a deeper understanding of these innovative therapeutic approaches."

Journal • Review • Oncology • Renal Cell Carcinoma

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. (PubMed, Lancet Oncol) - P1, P1/2, P2 | "These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible."

Journal • P1/2 data • Retrospective data • Hematological Disorders • Oncology • Pediatrics

Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). (PubMed, J Clin Oncol) - "Larotrectinib is highly active in patients with newly diagnosed NTRK fusion-positive solid tumors. Larotrectinib should be a frontline option for patients with IFS and other NTRK fusion-positive solid tumors. Local control with surgical resection remains important in the treatment of patients with IFS."

Journal • Fibrosarcoma • Oncology • Pediatrics • Sarcoma • Solid Tumor • NTRK

Exceptional response to sequential TRK inhibition in an epithelioid glioblastoma with NOS1AP-NTRK1 fusion (EANO 2026) - "First-line therapy consisted of standard radiochemotherapy with concomitant and adjuvant temozolomide from April to October 2021...Lomustine + bevacizumab was ineffective (PFS: 2 months)... Sequential NTRK-targeted therapy can produce exceptional and durable responses in NTRK1 fusion-positive eGB. Larotrectinib was initiated after progression based on the presence of a NOS1AP-NTRK1 fusion, targeting constitutive TRKA activation and downstream MAPK and PI3K-AKT signaling, resulting in rapid antitumor effects. Upon progression, repotrectinib, a CNS-penetrant second-generation TRK inhibitor, was selected to overcome potential resistance mutations and maintain pathway inhibition."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • BRAF • NTRK • NTRK1

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. (PubMed, ESMO Open) - P1, P1/2, P2 | "Larotrectinib achieved extremely durable responses, extended survival and had a favourable safety profile in treatment-naïve patients with TRK fusion cancers, supporting its use in this population. Elective discontinuation of larotrectinib may be feasible in selected paediatric patients, with response achievable after restarting larotrectinib in cases of recurrent off-therapy disease."

Journal • Endocrine Cancer • Fibrosarcoma • Oncology • Pediatrics • Salivary Gland Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Thyroid Gland Carcinoma

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. (PubMed, JCO Precis Oncol) - P1, P2 | "Larotrectinib is highly active with rapid and durable responses, extended survival benefit, and a favorable long-term safety profile in patients with advanced lung cancer harboring NTRK gene fusions, including those with CNS metastases. These findings support routine testing for NTRK fusions in patients with lung cancer."

Journal • Lung Cancer • Oncology • Solid Tumor • NTRK

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. (PubMed, Cancer) - "Tropomyosin receptor kinase (TRK) fusion proteins result from translocations involving the NTRK gene and cause cancer in a range of tumor types. Larotrectinib is an agent that specifically targets TRK fusion proteins and is approved for the treatment of patients with TRK fusion cancer. This study looked at how well larotrectinib worked in adult patients with sarcomas caused by TRK fusion proteins. Over half of patients had a durable response to larotrectinib, with no unexpected side effects. These results show that larotrectinib is safe and effective in adult patients with TRK fusion sarcomas."

Journal • Gastrointestinal Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Oncology • Osteosarcoma • Pediatrics • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • NTRK

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. (PubMed, Eur J Endocrinol) - P1, P1/2, P2 | "In TRK fusion-positive TC, larotrectinib demonstrates rapid and durable disease control and a favourable safety profile in patients with advanced disease requiring systemic therapy."

Journal • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. (ASCO 2022) - P1, P2 | "In this larger dataset, larotrectinib demonstrated rapid and durable responses, extended survival, and a favorable long-term safety profile in pts with advanced lung cancer harboring NTRK gene fusions, including in pts with CNS metastases. These results support testing for NTRK gene fusions in pts with lung cancer."

Clinical • Carcinoid Tumor • Immunology • Lung Cancer • Musculoskeletal Pain • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • NTRK • NTRK1 • NTRK3